Delivery Order SPE2DB25D3017-SPE2DB25FVKRD
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 5, 2025, for the supply of Viberzi 100 mg tablets (60-count packages) with a ceiling value of $3,030.63. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The order is scheduled for completion by June 6, 2025, and will...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp, the pharmaceutical distributor and healthcare solutions provider headquartered in Conshohocken, Pennsylvania, on July 24, 2025, for the supply of Viberzi 100 mg tablets (60-count). This firm fixed price delivery order, valued at $1,184.87, is classified as a non-set-aside contract and is expected to reach ultimate completion by July 25, 2025, with performance occurring at AmerisourceBergen's Conshohocken...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Viberzi 100 mg tablets (60-count) at a firm fixed price of $1,138.42. This non-set-aside contract, with an ultimate completion date of August 1, 2025, represents a delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Viberzi 75 mg tablets (60 count) valued at $2,354.21. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of June 20, 2025. The contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Viberzi 75 mg tablets (60-count units) with a ceiling value of $2,002.01. This is a firm fixed-price delivery order with an ultimate completion date of August 8, 2025, and represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location. The delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Viberzi 100 mg tablets (60-count units) with a ceiling value of $2,130.52. This competitively awarded, non-set-aside contract reflects a firm fixed price delivery order with an ultimate completion date of August 28, 2025. The vendor will perform from its corporate office location in Conshohocken, Pennsylvania. This delivery order is executed under AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a delivery order valued at $1,707.63 to AmerisourceBergen Drug Corp for 60 tablets of Viberzi 100 mg on August 5, 2025, with an ultimate completion date of August 6, 2025. This is a firm fixed price, non-set-aside contract with performance occurring at the company's corporate office in Conshohocken, Pennsylvania. The award represents a competitive delivery order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Viberzi 100 mg tablets (60-count units) under a firm fixed-price contract with a ceiling value of $1,716.59. The award, issued on June 9, 2025, with an ultimate completion date of June 10, 2025, represents a non-set-aside competitive procurement. The place of performance is listed as AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Viberzi 100 mg tablets (60-count units) with a ceiling value of $4,307.34. This is a firm fixed-price delivery order with no set-aside designation, awarded through competitive procedures. The order is set for ultimate completion by July 30, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child contract action,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Viberzi 100 mg tablets (60-count) valued at $1,914.82. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement valued through December 2026. The order is set to be completed by June 3, 2025, with...
- SPE2DB25D3017Indefinite Delivery Contract
- SPE2DB25D3017-SPE2DB25FVKRDDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Viberzi 100 mg tablets (60-count) with a ceiling value of $1,718.59. This is a firm fixed-price delivery order issued under a competitively awarded, non-set-aside procurement. The product will be delivered to the company's location in Conshohocken, Pennsylvania, with an ultimate completion date of September 17, 2025. This delivery order is issued as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp serves as a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The company's comprehensive pharmaceutical supply agreements with the DLA enable it to fulfill diverse medical needs across multiple therapeutic domains, including specialty medications, generic drugs, vaccines, and medical supplies for the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. Viberzi (linaclotide) is an FDA-approved gastrointestinal medication used in the treatment of irritable bowel syndrome with constipation, representing part of the company's broad portfolio of pharmaceutical products delivered through its federal contracting relationships.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 9/16/25 |